Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 135.5% from a year ago

Total equity stood at $17.58M at the end of Q1 FY2026, up 135.5% from a year earlier and down 1.0% from the prior quarter. Over 3 fiscal years it compounded at +58.6% a year.

Context

  • Total equity amounted to 88.8% of total assets at the end of Q1 FY2026, up 33.4 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +135.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$17.58M-1.0% QoQ
Last fiscal yearDec 2025
$17.75M+359.1% YoY
Year agoMar 2025
$7.46M+135.5% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+135.5%——
1 year+359.1%——
3-year CAGR+58.6%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
17.75M USD
Year-over-year change
+359.1%
4-year CAGR
+65.8%

Total Equity vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's Mar 2026 total equity of $17.58M is the 4th highest of the 9 companies compared; the peer median is -$2.4M.
  • Its year-over-year change of +135.5% is the 4th highest of 9, against a peer median of +27.9%.
  • Total equity amounts to 88.8% of total assets for COEP, versus a peer median of 105.2%.
COEP Competitors Peer median
Total Equity for COEP and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IPSCCentury Therapeutics, Inc.Mar 2026$264.74M +10.1%-19.3%81.1%
EQEquillium, Inc.Mar 2026$59.49M +462.4%-3.6%94.3%
CUECue Biopharma, Inc.Mar 2026$21.61M +228.4%-26.2%70.0%
COEPCoeptis Therapeutics, Inc.Mar 2026$17.58M +135.5%+58.6%88.8%
TELOTelomir Pharmaceuticals, Inc. Common StockMar 2026$4.96M +3180.1%—85.7%
OSTXOS Therapies IncorporatedMar 2026-$9.75M -1689.4%—133.6%
NRXPNRx Pharmaceuticals, Inc.Mar 2026-$13.82M +45.1%—116.1%
OTLKOutlook Therapeutics, Inc.Mar 2026-$28.99M +10.7%—132.4%
KPTIKaryopharm Therapeutics Inc.Mar 2026-$265.65M -29.0%—202.1%
Peer median (excluding COEP) -$2.4M+27.9%-19.3%105.2%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.18M3.79M1.47M532.89K5.67M
Short-term Investments0000676.6K
Net Receivables08.08K38.98K07.35K
Inventory00000
Other Current Assets00000
Total Current Assets2.18M3.94M1.75M1.05M7.35M
Property, Plant & Equipment (Net)31.85K71.46K108.88K59.78K18.4K
Goodwill00000
Intangible Assets4.55M3.55M2.55M541.88K361.25K
Long-term Investments003.5M5.69M7.86M
Tax Assets00000
Other Non-current Assets4.55M348.33K158.33K1.56M4.25M
Total Non-current Assets4.59M3.97M6.32M7.86M12.49M
Total Assets6.77M7.92M8.07M8.91M19.84M
Account Payables134.09K99.02K1.42M1.27M888.76K
Short-term Debt2.42M1.89M1.01M1.19M118.88K
Tax Payables00000
Deferred Revenue0000599.46K
Other Current Liabilities199.13K182K555.95K1.28M161.05K
Total Current Liabilities2.76M2.17M2.99M4.51M1.77M
Long-term Debt1.65M150K150K150K150K
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities01.13M557.25K359.25K167.63K
Total Non-current Liabilities1.65M1.29M768.43K528.13K317.63K
Total Liabilities4.41M3.46M3.76M5.04M2.09M
Common Stock3.55K1.96K3.53K212575
Retained Earnings(27.55M)(66.09M)(87.36M)(98.23M)(109.95M)
Accumulated OCI00000
Other Stockholders Equity000(1.56M)0
Minority Interest000682.06K506.16K
Total Equity2.35M4.45M4.31M3.87M17.75M
Total Debt4.08M2.06M1.22M1.4M268.88K
Net Debt1.9M(1.73M)(244.91K)866.17K(5.41M)

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.